Effect of clofibrate on blood viscosity in intermittent claudication.
Sixty-two patients with intermittent claudication associated with peripheral arterial diseases were treated with clofibrate, 2 g daily, for a minimum of six months. Progress was compared with that in a similar pretreatment period and also with that of a matched untreated control group of 27 patients. The most striking effect of clofibrate was a steep and sustained fall in whole-blood viscosity measured over a wide range of shear rates. This was associated with a significant fall in abnormally raised initial plasma-fibrinogen levels. An increased proportion of patients on treatment showed evidence of clinical improvement. Clofibrate had no effect on the susceptibility of red blood cells to autoxidation but it led to a significant shift in the red cell fatty acid pattern.
D001809:Blood Viscosity / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology*; D004912:Erythrocytes / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D005227:Fatty Acids / Q000097:blood; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007383:Intermittent Claudication / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D010084:Oxidation-Reduction; D014280:Triglycerides / Q000097:blood
D005227:Fatty Acids; D014280:Triglycerides; D005340:Fibrinogen; D002784:Cholesterol; D002994:Clofibrate